Pilot Study of RNS60 in Allergen-induced Bronchconstriction
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs RNS 60 (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Revalesio
- 03 Oct 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.
- 03 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.